V8 Nexus Hemoglobin Ultrascreen, V8 AFSA2 Hemo Control
Abnormal Hemoglobin Quantitation. 510(k) K192931, from Helena Laboratories, Corp. (Beaumont, TX). Product code GKA, class 2.
As of Nov 20, 2026, K192931 is an FDA 510(k) held by Helena Laboratories, Corp., substantially equivalent on Apr 19, 2022 after 915 days, with no recalls tied to it in FDA's recall database.
- Review time: 915 days
- Recalls: 0
The V8 Nexus Hemoglobin UltraScreen method is designed for the separation of normal hemoglobins (A, A2, and F) in human blood samples, and for the detection of major hemoglobins variants (S and C) by using a capillary zone electrophoresis (CZE) buffer with the V8 instrument. The V8 Nexus Hemoglobin UltraScreen test is indicated for use in patients 2 years of age and older.
- Sebia Capillarys Hemoglobin(E) With Capillarys 2K112491 · Sebia · May 24, 2012
- CAPI 3 NEONAT Hb, CAPILLARYS 3 DBS InstrumentK232027 · Sebia · Apr 4, 2024
- Premier Resolution SystemK222635 · Trinity Biotech (Primus Corporation, Dba Trinity Biotech) · Aug 4, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Oct 17, 2019
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7415
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files